{
  "emaEpar": [
    {
      "activeSubstance": "carmustine",
      "conditionIndication": "Carmustine is effective in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastasesSecondary therapy in non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s diseaseas conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin\u2019s disease / Non-hodgkin\u2019s lymphoma).",
      "inn": "carmustine",
      "marketingAuthorisationDate": "2018-07-18 00:00:00",
      "marketingAuthorisationHolder": "Obvius Investment B.V.",
      "medicineName": "Carmustine Obvius",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-obvius"
    }
  ],
  "fdaDrugLabel": [
    {
      "brand": "Gliadel",
      "indication": "1 INDICATIONS AND USAGE GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation ( 1 ) and recurrent glioblastoma as an adjunct to surgery ( 1 )",
      "manufacturer": "Arbor Pharmaceuticals",
      "splSetId": "38962a55-a514-4c48-bea5-f99a8da4beec"
    }
  ],
  "id": "Carmustine",
  "nciThesaurus": {
    "casRegistry": "154-93-8",
    "chebiId": "CHEBI:3423",
    "chemicalFormula": "C5H9Cl2N3O2",
    "definition": "An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily.",
    "fdaUniiCode": "U68WG3173Y",
    "identifier": "C349",
    "preferredName": "Carmustine",
    "semanticType": "Hazardous or Poisonous Substance",
    "subclassOf": [
      "C699"
    ],
    "synonyms": [
      "1,3-Bis(2-chloroethyl)-1-nitrosourea",
      "1,3-Bis(beta-chloroethyl)-1-nitrosourea",
      "BCNU",
      "Becenum",
      "Becenun",
      "BiCNU",
      "Bis(chloroethyl) Nitrosourea",
      "Bis-Chloronitrosourea",
      "CARMUSTINE",
      "Carmubris",
      "Carmustin",
      "Carmustine",
      "Carmustinum",
      "FDA 0345",
      "N,N'-Bis(2-chloroethyl)-N-nitrosourea",
      "N,N'-bis(2-chloroethyl)-N-nitrosourea",
      "Nitrourean",
      "Nitrumon",
      "SK 27702",
      "SRI 1720",
      "WR-139021",
      "carmustine"
    ]
  }
}